Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C.

[1]  K. Reddy,et al.  Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  S. Zeuzem,et al.  SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. , 2007, Gastroenterology.

[3]  I. Kerr,et al.  pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Silverman.  Viral Encounters with 2′,5′-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response , 2007, Journal of Virology.

[5]  P. Lengyel.  From RNase L to the multitalented p200 family proteins: an exploration of the modes of interferon action. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[6]  R. Silverman,et al.  Small self-RNA generated by RNase L amplifies antiviral innate immunity , 2007, Nature.

[7]  T. Sugimura,et al.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Marcellin,et al.  Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. , 2004, Journal of hepatology.

[9]  Tara L. Kieffer,et al.  Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C , 2007, Hepatology.

[10]  Thomas Lengauer,et al.  Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. , 2005, The Journal of infectious diseases.

[11]  B. Bacon,et al.  Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus , 2007, Hepatology.

[12]  J. Skehel,et al.  Interferon action—sequence specificity of the ppp(A2′p)nA-dependent ribonuclease , 1981, Nature.

[13]  P. Lengyel,et al.  Interferon action: RNA cleavage pattern of a (2'-5')oligoadenylate--dependent endonuclease. , 1981, Science.

[14]  Thomas Lengauer,et al.  Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon‐alpha‐based therapy in HCV‐1b‐infected patients , 2007, Journal of viral hepatitis.

[15]  R. Silverman,et al.  Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L. , 2007, Virus research.

[16]  N. Enomoto,et al.  Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. , 1995, The Journal of clinical investigation.

[17]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[18]  C. Bisbal,et al.  Cloning and Characterization of a RNase L Inhibitor. , 1995, The Journal of Biological Chemistry.

[19]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[20]  J. Hoofnagle.  Course and outcome of hepatitis C , 2002, Hepatology.

[21]  R. Silverman,et al.  Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[22]  H. El‐Serag.  Hepatocellular carcinoma and hepatitis C in the United States , 2002 .

[23]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[24]  B. Kronenberger,et al.  Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response , 2000 .

[25]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[26]  D. Barton,et al.  Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. , 2002, RNA.

[27]  B. Kronenberger,et al.  Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. , 2003, The Journal of infectious diseases.

[28]  Y. Chernajovsky,et al.  An interferon-induced phosphodiesterase degrading (2'-5') oligoisoadenylate and the C-C-A terminus of tRNA. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C , 2005 .

[30]  B. Williams,et al.  Interferon‐induced binding of nuclear factors to promoter elements of the 2‐5A synthetase gene. , 1988, The EMBO journal.

[31]  F. Foschi,et al.  Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection , 2005, Journal of viral hepatitis.

[32]  Robert H. Silverman,et al.  Expression cloning of 2-5A-dependent RNAase: A uniquely regulated mediator of interferon action , 1993, Cell.

[33]  Samir K. Gupta,et al.  Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data , 2000 .

[34]  Mark R. Player,et al.  The 2–5 A system: Modulation of viral and cellular processes through acceleration of RNA degradation , 1998, Pharmacology & Therapeutics.

[35]  R. Purcell,et al.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[37]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[38]  R. Silverman,et al.  A viral RNA competitively inhibits the antiviral endoribonuclease domain of RNase L. , 2008, RNA.

[39]  R. Silverman,et al.  2-5A-dependent RNase Molecules Dimerize during Activation by 2-5A (*) , 1995, The Journal of Biological Chemistry.

[40]  H. El‐Serag.  Hepatocellular carcinoma and hepatitis C in the United States , 2002, Hepatology.

[41]  E. Herrmann,et al.  Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses , 2002, Journal of Virology.

[42]  B. Bacon,et al.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.

[43]  S. Zeuzem,et al.  Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. , 2006, Gastroenterology.

[44]  T. Date,et al.  Full-length sequence of the genome of hepatitis C virus type 3a: comparative study with different genotypes. , 1994, The Journal of general virology.

[45]  E. Herrmann,et al.  Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. , 2001, Virology.

[46]  P. Marcellin,et al.  Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C , 2004, Annals of Internal Medicine.

[47]  Thomas Lengauer,et al.  Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C , 2005, Antiviral therapy.

[48]  Diego Jaitin,et al.  Upregulation of a small subset of genes drives type I interferon-induced antiviral memory. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[49]  R. Silverman,et al.  A Phylogenetically Conserved RNA Structure in the Poliovirus Open Reading Frame Inhibits the Antiviral Endoribonuclease RNase L , 2007, Journal of Virology.

[50]  I. Kerr,et al.  Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells , 1977, Nature.

[51]  T. Berg,et al.  Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. , 2005, Gastroenterology.